+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.

All AgesAll Genders
59 locations
O

Actively Recruiting

Researchers are observing patients who receive Siltartoxatug Injection, also known as Sintetol4, to prevent tetanus following injury. This large-sample, real-world registry aims to document injury and wound conditions and evaluate clinical outcomes related to tetanus prevention. The study focuses on collecting safety information and any adverse reactions after receiving the injection. Participants in this observational study receive Siltartoxatug Injection as part of their tetanus prophylaxis after injury. The study does not involve randomization or comparison groups but follows patients over time to monitor outcomes. A key part of the study is the follow-up at 90 days after administration to assess whether tetanus develops and to record any safety events. During the study, patient injury details and wound conditions will be carefully noted. Safety data will be selectively collected to identify any adverse reactions or serious events linked to Siltartoxatug use. The main outcome measure is the occurrence of tetanus within 90 days post-injection. Participants are followed for this 90-day period to evaluate treatment outcomes and safety.

All AgesAll Genders
4 locations
M

Actively Recruiting

Researchers are evaluating the agreement between four different test methods and a reference assay for MET overexpression in patients with untreated non-small cell lung cancer NSCLC. The study focuses on treatment-nave patients with unresectable locally advanced, metastatic, or recurrent NSCLC. It is a multicenter, prospective study sponsored by AstraZeneca, aiming to improve understanding of tumor gene profiling and MET concordance. Participants undergo next-generation sequencing NGS testing initially to determine their EGFR mutation status. Based on these results, participants are assigned to one of three cohorts those with specific EGFR mutations, those without actionable genomic alterations, and those with other actionable genomic alterations. Additional diagnostic tests such as MET IHC testing, PD-L1, and Her2 testing are performed for participants in the first cohort. During the study, participants provide tissue samples collected after diagnosis but before any antitumor treatment. The research team analyzes various biomarkers and treatment patterns up to 90 days after the last patient in. Participants are monitored through these tests and gene profiling to assess the concordance of different diagnostic methods. The total participation duration aligns with the study completion date in March 2027.

Age: 18Years +All GendersPhase Not Applicable
51 locations
S

Actively Recruiting

Researchers are conducting a multicenter, single-blind, randomized controlled trial to evaluate the safety and effectiveness of combined interventions for sarcopenia, a condition characterized by loss of muscle mass and strength. Participants who meet the diagnostic criteria for sarcopenia and are 30 years or older are included. The trial compares routine interventions alone and in combination with supplements to assess their impact on muscle health and physical function. Participants are divided into three groups a control group receiving routine care including nutritional guidance, progressive resistance exercise, safety advice, and treatment for complications over 24 weeks an experimental group 1 receiving the same routine care plus whey protein powder supplementation for 12 weeks at 60 grams per day in three doses and an experimental group 2 receiving routine care along with both whey protein powder and eldecalcitol capsules at 0.75 micrograms daily for 12 weeks. Liver and kidney function are monitored to adjust protein dosage if needed. Throughout the 24-week study, participants undergo regular assessments including general health evaluations, blood tests, muscle mass and strength measurements, and physical function tests like grip strength and 6-meter walking speed. Researchers also monitor adverse events to evaluate safety. The main outcome is muscle mass change, with secondary outcomes including muscle strength, walking speed, and incidence of adverse reactions.

Age: 30Years +All GendersPhase 4
5 locations
S

Actively Recruiting

Researchers are evaluating whether the combination of Bailing Capsules and Guben Kechuan Granules can help treat adults with stable bronchiectasis. This study also aims to determine the safety of these combined treatments compared to the standard Western medical treatment. The main questions focus on whether this combination reduces the number of acute exacerbations in patients with stable bronchiectasis. Participants in the experimental group will take Bailing Capsules orally four capsules three times a day plus Guben Kechuan Granules one bag three times a day alongside standard Western medical treatment for 24 weeks. The control group will receive only the standard Western medical treatment. Both groups will be monitored throughout the study period, which includes visits at weeks 4, 12, 24, and 48, with symptom diaries kept by participants. During the study, participants will visit the clinic for checkups and tests to assess lung function at 12, 24, and 48 weeks. Researchers will measure the number of acute exacerbations during treatment and follow-up periods at 24 and 48 weeks. Safety and treatment adherence will be monitored throughout the trial, which lasts for nearly a year, allowing a comprehensive evaluation of treatment effects and patient health.

Age: 18Years - 80YearsAll GendersPhase 4
5 locations
P

Actively Recruiting

This research aims to evaluate the safety and effectiveness of TQA2225AP025, a recombinant human FGF21-Fc fusion protein, in adults with Non-Alcoholic Steatohepatitis NASH. It is a randomized, double-blind, placebo-controlled Phase II study designed to assess how well two different doses of this treatment work in managing NASH, a liver condition characterized by fat buildup and inflammation. Participants will receive either 25mg or 50mg of TQA2225AP025 or a matching placebo, given by weekly subcutaneous injections for 48 weeks. The study includes two experimental groups receiving the different doses, and all treatments are administered under blinded conditions to assess the treatment effects accurately. During the study, participants will undergo liver biopsies at the start and after 48 weeks to measure changes in liver condition using the NASH CRN scoring system. Safety will be closely monitored by tracking any adverse events throughout the treatment period. The study is expected to provide detailed information on both the treatment impact on liver health and its safety profile over nearly a year of participation.

Age: 18Years - 75YearsAll GendersPhase 2
53 locations